View Older Stories View More Recent Stories

Jul 21, 2023 05:36AM AbbVie (ABBV) Receives Positive CHMP Opinion for Epcoritamab
Jul 21, 2023 04:30AM AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Jul 6, 2023 08:00AM AbbVie to Host Second-Quarter 2023 Earnings Conference Call
Jun 28, 2023 06:30AM Kineta Expands Board of Directors with Biotech Industry Leaders Kim Drapkin and Scott Dylla
Jun 28, 2023 05:22AM AbbVie (ABBV) and Genmab (GMAB) Report Positive Topline Results from Phase 1/2 EPCORE NHL-1 Trial
Jun 27, 2023 06:50PM AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
Jun 27, 2023 06:49PM Genmab and AbbVie Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody® CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
Jun 26, 2023 08:00AM AbbVie Employees Volunteer During 8th Annual "Week of Possibilities" to Support Communities Globally
Jun 23, 2023 08:05AM AbbVie (ABBV) Secures Positive CHMP Opinion for Atogepant for the Preventive Treatment of Adults with Migraine
Jun 23, 2023 08:04AM AbbVie Secures Positive CHMP Opinion for Atogepant for the Preventive Treatment of Adults with Migraine
Jun 22, 2023 01:13PM AbbVie Declares Quarterly Dividend
Jun 22, 2023 07:01AM Genmab A/S (GMAB) Announces Epcoritamab Added to National Comprehensive Cancer Network
Jun 22, 2023 07:00AM Genmab Announces Epcoritamab Added to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for ‘B-Cell Lymphomas’
Jun 22, 2023 07:00AM Genmab Announces Epcoritamab Added to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for ‘B-Cell Lymphomas’
Jun 15, 2023 08:45AM AbbVie (ABBV) Reports Risankizumab Met Primary and Key Secondary Endpoints in Phase 3 Maintenance Study
Jun 15, 2023 08:45AM Risankizumab (SKYRIZI®) Met Primary and Key Secondary Endpoints in 52-Week Phase 3 Maintenance Study in Ulcerative Colitis Patients
Jun 13, 2023 08:45AM BOTOX® Cosmetic (onabotulinumtoxinA) Announces the Winners of the IFundWomen Grant Program
Jun 9, 2023 03:01AM Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas at European Hematology Association (EHA) Annual Meeting 2023
Jun 9, 2023 03:00AM AbbVie's VENCLYXTO®/VENCLEXTA® (venetoclax) Continues to Show Sustained Progression-Free Survival (PFS) in Chronic Lymphocytic Leukemia (CLL) Patients
Jun 6, 2023 08:00AM AbbVie to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
May 31, 2023 02:30AM Phase 2 Study of Upadacitinib (RINVOQ®) Alone or as a Combination Therapy Meets Primary and Key Secondary Endpoints in Patients with Systemic Lupus Erythematosus
May 25, 2023 08:45AM AbbVie (ABBV) Announces NEJM Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Upadacitinib (RINVOQ®) in Crohn's Disease
May 25, 2023 08:45AM New England Journal of Medicine Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Upadacitinib (RINVOQ®) in Crohn's Disease
May 24, 2023 09:03AM AbbVie (ABBV) Presents Long-Term Data Further Supporting the Efficacy and Safety Profile of RINVOQ
May 24, 2023 09:00AM AbbVie Presents Long-Term Data Further Supporting the Efficacy and Safety Profile of RINVOQ® (upadacitinib) Across Multiple Rheumatic Diseases at the EULAR 2023 Congress
May 19, 2023 12:34PM Genmab (GMAB) EPKINLY Approved by FDA as First and Only Bispecific Antibody to Treat Adults with R/R Diffuse Large B-cell Lymphoma
May 19, 2023 12:34PM EPKINLY™ (epcoritamab-bysp) Approved by U.S. FDA as the First and Only Bispecific Antibody to Treat Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
May 18, 2023 12:27PM AbbVie (ABBV) Announces FDA Approval of RINVOQ as a Once-Daily Pill for Moderately to Severely Active Crohn's Disease in Adults
May 18, 2023 12:25PM U.S. FDA Approves RINVOQ® (upadacitinib) as a Once-Daily Pill for Moderately to Severely Active Crohn's Disease in Adults
May 15, 2023 08:46AM AbbVie (ABBV) Announces FDA Approval of SKINVIVE by JUVÉDERM
May 15, 2023 08:45AM SKINVIVE™ by JUVÉDERM® Receives U.S. FDA Approval
May 6, 2023 07:30AM AbbVie Releases New Data Demonstrating Breadth of Its Gastroenterology Portfolio at 2023 Digestive Disease Week®
May 2, 2023 08:00AM AbbVie to Present at the Bank of America Securities Healthcare Conference
Apr 27, 2023 07:32AM AbbVie Reports First-Quarter 2023 Financial Results
Apr 21, 2023 12:01AM AbbVie Announces Late-Breaking Results from Phase 3 Trial Evaluating Atogepant (QULIPTA®) for the Preventive Treatment of Episodic Migraine Among Patients with Prior Treatment Failure at the 2023 AAN
Apr 18, 2023 10:04AM Allergan Aesthetics Celebrates the Journeys of Women Surgeons with LIMITLESS
Apr 18, 2023 05:49AM AbbVie (ABBV) Announces FDA Approval of QULIPTA for Adults With Chronic Migraine
Apr 17, 2023 07:41PM U.S. FDA Approves QULIPTA® (atogepant) for Adults With Chronic Migraine
Apr 17, 2023 05:32AM AbbVie (ABBV) Announces EU Approval of RINVOQ for Moderately to Severely Active Crohn's Disease
Apr 17, 2023 02:00AM AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Moderately to Severely Active Crohn's Disease
Apr 12, 2023 11:00AM AbbVie Invites College Students Living with Cystic Fibrosis to Apply for the AbbVie CF Scholarship for the 2023-2024 Academic School Year
Apr 4, 2023 08:00AM AbbVie to Host First-Quarter 2023 Earnings Conference Call
Mar 29, 2023 09:00AM Allergan Aesthetics* to showcase 360° approach to clinical practice, aesthetic products, and patients with expert-led symposia at AMWC 2023
Mar 23, 2023 09:02AM AbbVie (ABBV) Advances Upadacitinib to Phase 3 Trial in SLE
Mar 23, 2023 09:00AM AbbVie Advances Upadacitinib (RINVOQ®) to Phase 3 Clinical Trials in Systemic Lupus Erythematosus
Mar 23, 2023 08:31AM AbbVie (ABBV) Announces Risankizumab Achieves Primary and All Secondary Endpoints in Phase 3 Induction Study in Patients With Ulcerative Colitis
Mar 23, 2023 08:30AM Risankizumab (SKYRIZI®) Achieves Primary and All Secondary Endpoints in Phase 3 Induction Study in Patients With Ulcerative Colitis
Mar 22, 2023 08:45AM AbbVie (ABBV) Provides Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa) New Drug Application
Mar 22, 2023 08:45AM AbbVie Provides Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa) New Drug Application
Mar 20, 2023 05:57AM AbbVie (ABBV) Reports Late-Breaking Data of SKYRIZI in Plaque Psoriasis Patients With a Prior Suboptimal Response to IL-17 Inhibitor Therapy
View More Recent Stories View Older Stories